Fibrocell Science, Inc. operates as a autologous cell therapy company, which focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. Its clinical and pre-clinical programs include treatments for restrictive burn scars, vocal cord scars, and acne scars. The company was founded on September 1, 2009 and is headquartered in Exton, PA.
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company's gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.